CLNN250117C3000
- 0.05
- 0.000.00%
Clene Newsroom
Food Inflation: These Are the 'Problem Spots' for Consumers
Global food prices have rebounded for the first time in three years, potentially increasing the burden on consumers.
The rebound in Global food prices may raise Consumer grocery spending costs this year.
Clene Secures $10M Debt Facility to Enhance Position
Press Release: Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan
Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan
Maxim Group Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $20
Promising Prospects for Clene's ALS Treatment: Buy Recommendation Backed by Robust Data and Regulatory Progress
IBN Coverage: Clene (NASDAQ: CLNN) Advances CNM-Au8 in ALS With FDA Guidance on Accelerated Approval Pathway
Clene Gains FDA Support for ALS Treatment Approval
Express News | Clene Inc. - Plans Nda Submission for ALS in Mid-2025
Express News | Clene Inc. - to Begin Phase 3 Restore-ALS Trial Before Nda Submission
Express News | Clene Inc. - FDA Recommends Follow-up Meeting for Accelerated Approval Pathway
Express News | Clene Inc. - FDA Recommends Clene Leverage Additional Nfl Data for ALS
Express News | FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional Cnm-AU8® Biomarker Data in ALS
FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8 Biomarker Data in ALS
Benchmark Maintains Buy on Clene, Lowers Price Target to $84
Clene Price Target Cut to $83.00/Share From $86.00 by Canaccord Genuity
Clene Price Target Maintained With a $23.00/Share by D. Boral Capital
Clene Is Maintained at Buy by D. Boral Capital
Clene Analyst Ratings